AKOYA BIOSC. DL-,00001 Logo
US00974H1041
A3CM1B
AKYA

AKOYA BIOSC. DL-,00001

Loading quotes...

Forecast

The analysts' average price target is €4.46 (+301.80%). The median is €5.37 (+383.78%).

Buy
  2
Hold
  7
Sell
  0

  • Quanterix unveils strategy for 2025 and targets cash-flow break-even by 2026

    At the Canaccord Genuity growth conference, Quanterix presented its strategic direction, cited $85 million in synergies from the Akoya acquisition and set a goal of reaching cash-flow break-even by 2026. The consumables business remains robust with pro-forma revenue of around $100 million, and the new SMO-one platform and the Lucent AD Complete test are expected to drive diagnostic growth. Quanterix reported mixed operational trends (declines in the accelerator and academic businesses) but sees accelerating synergies and anticipates Akoya-related revenue in H2. » More on de.investing.com

Financials

In the last year, AKOYA BIOSC. DL-,00001 had revenue of €78.49M and net profit of -€53.21M
(EUR) 2024
YoY
Revenue 78.49M 10.21%
Gross profit 46.01M 9.66%
Net profit -53.21M 7.11%
EBITDA -35.69M 13.54%

Fundamentals

Metric Value
Market capitalization
€57.65M
Number of shares
49.95M
52-week high/low
€3.06 - €0.83
Dividends No
Beta
1.35
P/E ratio
-1.15
PEG ratio
-0.03
P/B ratio
8.39
P/S ratio
0.79

Company profile

Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers Proxima, a cloud-based platform to store, analyze, and share spatial data; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.

Name
AKOYA BIOSC. DL-,00001
CEO
Brian McKelligon
Headquarters Marlborough, ma
USA
Website
Sector
Health Care
Industry
Health Care Equipment & Supplies
IPO
04/16/2021
Employees 205

Ticker symbols

Exchange Symbol
NASDAQ
AKYA
🍪

Parqet  uses cookies. Learn more